ArticleJournal of thoracic disease2026
Global burden and trends of tracheal, bronchus, and lung cancer in adolescents and young adults: a secondary analysis of the Global Burden of Disease Study 2021.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tracheal, bronchus, and lung (TBL) cancer is a major global cause of cancer-related morbidity and mortality. Adolescents and young adults (AYAs, ages 15-39 years) represent a distinctive demographic with unique epidemiological characteristics-including sex-specific trends, differing risk factor profiles, and distinct biological features-yet they are often overlooked in global cancer assessments. Understanding the TBL cancer burden in this age group is critical as they may serve as a sentinel population for emerging risk exposures including changing smoking patterns, e-cigarette use, and air pollution. This study aimed to analyze the burden of TBL cancer among AYAs in 204 countries and regions from 1990 to 2021, providing a basis for clinicians and public health institutions to formulate prevention strategies and optimize clinical treatment plans. Methods: Data on TBL cancer in AYAs were obtained from the Global Burden of Disease (GBD) Study 2021. We extracted incidence, prevalence, mortality, and disability-adjusted life years (DALYs) for TBL cancer in AYAs from 1990 to 2021. Age-standardized rates were derived using GBD population denominators. Analysis was stratified by age, sex, Socio-Demographic Index (SDI), and nationality. Trends were evaluated through estimated annual percentage change (EAPC) and percentage variation, with 95% uncertainty intervals (UIs) presented. Results: In 2021, the global burden included 28,004 new cases (age-standardized rate: 0.94 per 100,000, 95% UI: 0.85-1.03), 71,750 prevalent cases (rate: 2.41 per 100,000, 95% UI: 2.17-2.66), 22,622 deaths (rate: 0.76 per 100,000, 95% UI: 0.68-0.84), and 1,291,020 DALYs (rate: 43.4 per 100,000, 95% UI: 39.02-47.75). Since 1990, case counts increased by 5% for incidence and 19% for prevalence, while deaths and DALYs declined by 3% each. Females showed significant increases in cases and prevalence [percentage change (100%): 0.4], whereas changes in males were more modest. The 35-39 age group bore the highest burden (15,420 cases, rate: 2.75 per 100,000, 95% UI: 2.45-3.06). Middle SDI regions accounted for approximately 40% of the global burden, while the steepest increases occurred in low SDI regions. Conclusions: The global burden of TBL cancer in AYAs varies substantially by age, sex, and socioeconomic development. Prevention strategies should prioritize tobacco and nicotine control among young people, reduction of environmental and occupational exposures, strengthening of healthcare infrastructure in low-resource settings, and narrowing inequalities in early diagnosis and treatment access.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.